UBS Initiates Certara(CERT.US) With Hold Rating, Announces Target Price $10
UBS has initiated coverage on Certara (CERT.US) with a Hold rating. The firm has set a price target of $10 for the company's stock.
Certara Launches Marvin Cloud Worldwide, Bringing Professional Chemical Structure Drawing to Independent Scientists and Students
Certara, Inc. announced the worldwide availability of Marvin Cloud, a browser-based, cloud-hosted chemical sketching platform developed by its subsidiary, Chemaxon. This platform aims to provide independent scientists, students, and academics with access to professional-grade chemical structure drawing tools without requiring institutional deployment. Marvin Cloud offers core Marvin capabilities through individual subscriptions with flexible pricing, continuing Chemaxon's tradition of supporting scientific breakthroughs in chemistry.
CERT Downgraded by UBS -- Rating Changed to Neutral
UBS has downgraded Certara (CERT) to a Neutral rating, maintaining a price target of $10.00. Despite the downgrade, GuruFocus assesses CERT as 24.5% undervalued with a GF Value™ of $12.23 and a solid GF Score™ of 74. Seven gurus hold CERT, with five adding to their positions, indicating continued investor interest despite the cautious analyst outlook.
UBS Downgrades Certara to Neutral From Buy, $10 Price Target
UBS has downgraded Certara (NASDAQ: CERT) to Neutral from Buy, setting a new price target of $10. This adjustment reflects a revised outlook on the company's stock performance.
UBS resumes Certara stock coverage with neutral rating, $10 target By Investing.com
UBS has resumed coverage of Certara Inc. (NASDAQ:CERT) with a Neutral rating and a $10.00 price target, noting the stock is inexpensive historically but fairly valued against peers. Despite the stock appearing undervalued according to InvestingPro data, UBS highlights limited near-term catalysts and visibility into software growth and margin expansion. The firm also pointed out that Certara's cost savings initiatives are being offset by R&D investments, hindering margin improvement.
UBS resumes Certara stock coverage with neutral rating, $10 target By Investing.com
UBS has resumed coverage of Certara Inc. (NASDAQ:CERT) with a Neutral rating and a $10.00 price target, noting the stock is inexpensive historically but fairly valued against peers. While InvestingPro data suggests it's undervalued, UBS points to a muted near-term catalyst path and limited visibility into software growth and margin expansion as challenges. Certara recently missed Q2 2026 financial expectations, with adjusted earnings of $0.08 per share on revenue of $93.3 million, falling short of analyst projections.
Certara, Inc. (CERT) Stock forecasts
This article provides stock forecasts for Certara, Inc. (CERT) and includes general market data for various global indices and cryptocurrencies. It appears to be a stub or an article with missing content, as it primarily displays navigation and market data without specific analysis for Certara. The page also shows an error message for data retrieval.
Certara stock holds steady after recent earnings update
Certara stock is trading near recent levels on Nasdaq following its latest quarterly earnings release, which showed mixed revenue and profit trends. The company, a life-sciences software specialist, reported steady but not explosive revenue growth and healthy EBITDA margins, though net income was below prior-year peaks due to increased investments. Investors are evaluating its valuation and growth profile against sector peers, with analyst consensus generally constructive but tempered by more conservative growth assumptions.
Certara Launches External Data Accelerator for CDISC Standards Compliance
Certara has launched its External Data Accelerator to address the challenges of managing external clinical study data and ensuring compliance with CDISC standards. This solution integrates senior external data specialists with Pinnacle 21 Data Exchange to validate vendor data against FDA-used standards *before* it enters the study database, significantly reducing the cost and time associated with late-stage data remediation. The accelerator aims to prevent standards problems from surfacing at submission by enforcing conformance at the study setup phase.
This Certara Insider Increased Their Holding In The Last Year
The article indicates that an insider at Certara has increased their holdings in the company over the past year. This action by an insider often suggests a belief in the company's future prospects. Further details would be needed to understand the significance of this increase.
New RSU award sets 2027–2028 vesting for Certara (CERT) interim CFO
Certara, Inc. (CERT) has granted its Interim CFO, Mohammed Faiz, 63,532 Restricted Stock Units (RSUs) under the Certara 2020 Incentive Plan. These RSUs will vest in two equal installments on July 15, 2027, and July 15, 2028, contingent on his continued service. Each RSU represents a contingent right to one share of common stock or its cash equivalent, with the grant formalized on September 1, 2026.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
Pomerantz LLP is investigating Certara, Inc. (NASDAQ: CERT) for potential securities fraud and unlawful business practices. This investigation follows Certara's first-quarter 2026 financial results, which showed a decline in services revenue and bookings, and prompted a 19% drop in the company's stock price. Investors are encouraged to contact Pomerantz LLP to learn more about joining the class action.
Certara (NASDAQ: CERT) officer lines up $300K stock sale
Certara officer Leif Pedersen has filed a Rule 144 notice, indicating a potential sale of 36,066 shares of CERT common stock, valued at $300,069.12. These shares were acquired through restricted stock vesting on April 1, 2026. The sale will be executed through Fidelity Brokerage Services LLC, and Certara reported 152,538,780 shares outstanding as of September 3, 2026.
Certara, Inc. - Common Stock (NQ: CERT)
This article provides a list of recent news headlines and press releases related to Certara, Inc. (NQ: CERT). The news covers financial results, investor conferences, stock performance, share buyback plans, and the launch of new AI-driven solutions to reduce animal testing. Several entries highlight analyst opinions and market reactions to Certara's announcements and industry trends.
Tejara Capital Ltd Takes $8.47 Million Position in Certara, Inc. $CERT
Tejara Capital Ltd recently purchased a new position of 1,292,721 shares in Certara, Inc. (NASDAQ:CERT) valued at approximately $8.47 million, making it their 9th biggest position. Other institutional investors also adjusted their holdings in Certara during the second quarter. Analyst ratings for Certara are mixed, with an average "Hold" rating and an average price target of $8.28.
Guardian Small Cap Value Diversified VIP Fund's Certara Inc(CERT) Holding History
The Guardian Small Cap Value Diversified VIP Fund holds 242,957 shares of Certara Inc (CERT), valued at $1.59 million, representing 1% of its portfolio. The fund initiated its position in Q2 2026 with an average purchase price of $5.64 per share. As of the latest data, the fund has an estimated gain of $573,378.52 on its CERT holdings, marking a 41.84% return.
The Technical Signals Behind (CERT) That Institutions Follow
This article from Stock Traders Daily analyzes Certara Inc. (NASDAQ: CERT) using AI models to provide technical signals for institutional trading strategies. It highlights mixed sentiment, suggesting choppy conditions, and outlines position, momentum, and risk hedging strategies with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal strengths and support/resistance levels for near-term, mid-term, and long-term horizons.
Royal Bank of Canada Trims Holdings in Certara, Inc. $CERT
Royal Bank of Canada reduced its stake in Certara, Inc. by 19.5% in the first quarter, selling 245,200 shares and retaining over 1 million shares. This comes as Certara reported disappointing quarterly results, missing EPS and revenue expectations, with a 10.8% year-over-year revenue decline and a negative net margin. Despite mixed analyst sentiment leaning towards a "Hold" rating with an average price target of $8.28, institutional investors collectively own a significant 73.96% of the company.
Loss-Making Certara, Inc. (NASDAQ:CERT) Expected To Breakeven In The Medium-Term
This article discusses Certara, Inc.'s financial outlook, focusing on analyst expectations for the company to reach breakeven profitability within the next two years. It highlights the average analyst forecast for revenue growth, the substantial cash balance, and the current valuation based on price-to-sales. The analysis also touches on the potential risks and opportunities associated with Certara's path to profitability.
Renaissance Technologies LLC Has $2.02 Million Position in Certara, Inc. $CERT
Renaissance Technologies LLC significantly increased its stake in Certara, Inc. (NASDAQ:CERT) by 1,097.6% in the first quarter, now holding 354,500 shares valued at $2.02 million. Other institutional investors have also adjusted their positions in Certara, with a total of 73.96% of the company's stock owned by institutional investors and hedge funds. Despite recent earnings missing analyst estimates, Certara maintains a consensus "Hold" rating from analysts with a target price of $8.28.
Certara, Inc. (CERT) Stock Forecasts
The article provides a stock forecast for Certara, Inc. (CERT), a company focused on accelerating medicines using biosimulation software. It highlights an Argus research report from August 5, 2026, which includes a current price of $8.13 and a price target for CERT. The content encourages users to upgrade to premium for full report access and related research.
How Investors Are Reacting To Certara (CERT) Expanding Buybacks Amid Wider Losses And Leadership Changes
Certara (CERT) recently reported Q2 2026 results with higher sales but significantly wider net losses. In response, the company expanded its share repurchase authorization to $150 million and announced leadership changes. This has led to questions about Certara's balance between growth investments, leadership focus, and capital returns, especially as it continues to invest in its biosimulation and AI platforms.
Certara, Inc. (CERT) stock price, news, quote and history
This Yahoo Finance page provides comprehensive information on Certara, Inc. (CERT), including its current stock price, historical data, and key financial metrics. It details the company's biosimulation software and services for drug discovery and development, along with performance over various periods compared to the S&P 500. The page also offers analyst insights, valuation measures, and tools to compare CERT with similar companies in the Health Information Services industry.
Certara Corrects EBITDA Disclosure in Earnings Presentation
Certara announced a correction to its second-quarter 2026 earnings presentation regarding the adjusted EBITDA of its recently divested Regulatory and Medical Writing business. The company clarified that the business generated approximately $23 million of adjusted EBITDA in 2025 when excluding unallocated corporate expenses, a correction from the previously stated $17 million that included unallocated overhead costs. This adjustment primarily impacts disclosure accuracy and does not affect past financial results, year-over-year comparisons, or its 2026 financial outlook.
Certara, Inc. (NASDAQ: CERT) corrects 2025 EBITDA for divested unit
Certara, Inc. (NASDAQ: CERT) has issued a clarification regarding the 2025 adjusted EBITDA of its recently divested Regulatory and Medical Writing business. The company initially misstated that the $17 million adjusted EBITDA figure excluded unallocated overhead costs, but now confirms it includes them. Additionally, excluding unallocated corporate expenses that will remain with Certara, the divested unit generated approximately $23 million in adjusted EBITDA in 2025.
Form 8K Certara Inc For: 7 August By Investing.com
This article announces the filing of a Form 8K by Certara Inc. on August 7th. It is a brief financial news item published by Investing.com, indicating a corporate event that Certara Inc. deemed important enough to report via an 8K filing. The content itself is very short, primarily serving as a notification.
Certara, Inc. $CERT Shares Acquired by Quantinno Capital Management LP
Quantinno Capital Management LP significantly increased its stake in Certara, Inc. (NASDAQ:CERT) by 412.5% in the first quarter, acquiring an additional 796,007 shares. Despite this increased institutional interest, Certara missed its Q1 earnings and revenue expectations, reporting $0.08 EPS against an expected $0.09 and $93.27 million in revenue compared to a forecast of $98.09 million. Analysts currently hold a consensus "Hold" rating for the stock with an average price target of $8.28.
Form 8K Certara Inc For: 7 August By Investing.com
This article from Investing.com announces the filing of a Form 8K by Certara Inc. on August 7th. It is a brief news item indicating a regulatory filing by the company. The content also includes a broader financial news portal layout with market data and other articles.
Certara, Inc. $CERT Shares Sold by Sei Investments Co.
Sei Investments Co. significantly reduced its stake in Certara, Inc. (NASDAQ:CERT) by 43.6% in the first quarter, selling 479,880 shares but retaining 620,967 shares valued at approximately $3.54 million. Despite other institutional investors increasing their holdings, Certara reported a quarterly EPS of $0.08, missing the consensus estimate of $0.09, and revenue of $93.27 million, below expectations of $98.09 million, representing a 10.8% year-over-year decline. Analyst sentiment remains mixed, with a consensus "Hold" rating and an $8.28 target price for the stock.
Certara, Inc. (NASDAQ:CERT) Given Average Rating of "Hold" by Analysts
Analysts have given Certara, Inc. (NASDAQ:CERT) an average "Hold" rating, with a consensus 12-month price target of $8.95, though several brokerages recently lowered their targets. The company's recent financial results fell short of expectations, reporting quarterly EPS of $0.08 against a $0.09 consensus and revenue of $93.27 million against an expected $98.09 million, representing a 10.8% year-over-year decline. Despite this, the stock opened at $8.01, is up 2.7%, and institutional ownership remains high at approximately 73.96% of outstanding shares.
Certara Announces Leadership Change in Commercial Executive Role
Certara, Inc. announced that Leif E. Pedersen has departed from his role as President and Chief Commercial Officer, effective August 1, 2026. Pedersen will remain as a Senior Advisor through December 31, 2026, to facilitate the transition, and will receive severance benefits as per his employment agreement. An analyst rating on Certara stock is a Buy with an $8.00 price target, while TipRanks’ AI Analyst, Spark, rates CERT as Neutral due to strong financials but weak valuation signals.
Certara, Inc. Stock 12‑Month Price Target Cut to $7.83
Analysts have reduced the average 12-month price target for Certara, Inc. (CERT) stock from $7.93 to $7.83, with individual forecasts ranging from $6 to $9 per share. Despite the cut in the price target, the consensus rating among 13 covering analysts remains a "Buy," with 5 Buy, 8 Hold, and 0 Sell recommendations.
Certara Announces Leadership Change in Commercial Executive Role
Certara, Inc. announced that Leif E. Pedersen has departed from his role as President and Chief Commercial Officer, effective August 1, 2026. He will remain as a Senior Advisor until December 31, 2026, to assist with the transition. This leadership change in a key commercial executive role has potential implications for Certara's go-to-market strategy in the biopharmaceutical sector.
Certara Q2 2026 earnings: Software growth offsets weaker services
Certara (Nasdaq: CERT) reported Q2 2026 revenue of $93.3 million, up 1%, with diluted EPS swinging to a $0.04 loss. Software growth drove revenue, counteracting weaker services, higher operating expenses, and unfavorable currency movements that impacted GAAP profitability. The company reaffirmed its revenue outlook, expecting software strength and improved services in the second half, while reorganization efforts aim for $13 million in run-rate savings despite near-term costs.
Certara (CERT) Stock Price Faces Loss Pressure Despite Software Gains
Certara's stock price declined 4.7% after its Q2 earnings report, despite a strong performance in its software segment. The company reported a net loss from continuing operations of US$6.1m, contrasting with a healthy 28.1% adjusted EBITDA margin. While software revenue increased and now constitutes 53% of total revenue, overall revenue growth remains modest at 1%, raising questions about its valuation and long-term profitability.
Bronstein, Gewirtz & Grossman, LLC Encourages Certara, Inc. (CERT) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Certara, Inc. (NASDAQ:CERT) following a significant drop in its stock price. The investigation stems from Certara's Q1 2026 financial results, which reported declines in services revenue and bookings, and an announced exit from its regulatory business. Investors who purchased Certara securities are encouraged to contact the firm for more information regarding the securities investigation.
Certara, Inc. Stock 12‑Month Price Target Raised to $7.63, Implies 7% Downside
Certara, Inc.'s average stock price target has increased from $7.53 to $7.63, according to 10 analysts, with forecasts ranging from $6 to $10 per share. This updated target suggests a potential 7% downside based on the August 3 closing price. The consensus rating remains a "Buy" among 13 analysts, comprising 5 Buys and 8 Holds.
Certara, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:CERT) 2026-08-04
This article presents the slide deck published by Certara, Inc. in conjunction with their 2026 Q2 earnings call held on August 4, 2026. The company reported Q2 EPS of $0.08, missing by $0.01, and revenue of $93.27M, a 10.81% year-over-year decrease, missing by $4.81M. The information is provided by SA Transcripts, Seeking Alpha's transcripts team.
Certara Falls Short on Q2 2026: $0.08 EPS vs $0.10 Expected
Certara, Inc. reported Q2 2026 adjusted diluted earnings per share of $0.08, missing the consensus estimate of $0.10 by 11.1%. Revenue increased modestly by 1.0% year-over-year to $93.3 million, with the Software segment showing stronger growth. The company's stock remained largely unchanged, reflecting mixed analyst sentiment with a predominance of hold ratings.
How Certara’s Widening Losses Amid Modest Sales Growth Will Impact Certara (CERT) Investors
Certara, Inc. (CERT) reported a significant widening of its net loss to US$55.27 million in Q2 2026, despite modest sales growth. This financial deterioration raises concerns about the company's cost discipline and the return on its R&D and AI investments, particularly given its recent partnership with NVIDIA. Investors are advised to consider the execution risk associated with new platforms and acquisitions as the company navigates its strategy focused on biosimulation and AI-enabled drug development.
Earnings call transcript: Certara Q2 2026 miss sends shares down 16%
Certara reported Q2 2026 adjusted earnings of $0.08 per share and revenue of $93.3 million, missing analyst expectations and causing its stock to drop 16.08%. The company noted solid software growth but weakness in services and higher costs, reaffirming its full-year guidance while emphasizing a shift towards software and AI-driven product development. Management highlighted pipeline growth and strategic changes, including a new Chief Commercial Officer and an NVIDIA partnership, as key drivers for future sustainable double-digit growth.
Certara, Inc. 2026: Revenue $93.27M, EPS ($0.36) — 10-Q Summary
Certara, Inc. reported its first-quarter 2026 results, showing a 1% revenue increase to $93.27M. Despite this growth, the company experienced a significant net loss of $55.27M, or ($0.36) diluted EPS, compared to a smaller loss in the prior year. Revenue growth was primarily driven by a 6% increase in software, and the company is focusing on core offerings after divesting its Regulatory & Medical Writing business.
Precision Trading with Certara Inc. (CERT) Risk Zones
The article provides a detailed analysis of Certara Inc. (CERT) using AI models to suggest trading strategies across different risk profiles and holding periods. It highlights a strong near-to-mid-term sentiment but a weak long-term outlook, identifying specific entry, target, and stop-loss zones for position, momentum breakout, and risk hedging strategies. The analysis emphasizes risk management and offers real-time signals and multi-timeframe insights for traders.
Certara earnings up next: Can AI strategy stem revenue decline? By Investing.com
Certara, a biosimulation software provider, is set to report its second-quarter results, with analysts expecting an EPS increase but a 6% revenue decline year-over-year. Investors will be watching whether the company's new leadership and AI-focused strategy, including a partnership with NVIDIA and increased R&D in AI features, can reverse its troubling revenue trajectory and restore confidence. The key questions revolve around customer spending, competitive pressures, and the impact of operational changes on profitability.
Certara Inc (CERT) Institutional Confidence
Certara Inc (CERT) has an institutional shareholding score of 10.00, placing it first in the Software & IT Services industry. The institutional shareholding proportion is 115.63%, a decrease of 12.27% quarter-over-quarter. Bill Nygren | OAKMX is the largest institutional shareholder, holding 1.51M shares, representing 0.92% of outstanding shares.
Certara Inc (CERT) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Certara Inc (CERT), noting its current valuation score of 9.16 within the Software & IT Services industry. It highlights the company's P/E ratio, which stands at -85.20, and mentions that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed. The market capitalization for Certara Inc is reported as 1.24 billion USD.
Certara Number of Employees 2026 | Employee Count & Headcount Data
Certara, Inc. (CERT) has approximately 1,618 total employees worldwide as of March 2026, representing a 4.9% growth from 1,542 employees in 2023. The company is actively hiring, although job postings have declined by 19.4% in 2026 compared to 2025. Certara's workforce is concentrated in North America, and the average salary is $86,590.
Certara, Inc. (CERT) Stock Analysis: A Healthcare Investment With Limited Upside Potential
Certara, Inc. (CERT) is a significant player in the health information services industry, offering biosimulation solutions for drug discovery and clinical research. Despite its innovative technology and robust free cash flow, the company is not currently profitable, with negative EPS and return on equity. Analyst ratings show cautious optimism, with an average target price suggesting a slight downside, indicating limited immediate upside potential for investors.
Certara Inc (CERT) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Certara Inc (CERT), detailing its current price momentum score, support and resistance levels, and various technical indicators. It shows that CERT's stock price is trading between resistance at $8.68 and support at $6.70, suggesting suitability for range-bound swing trading. The analysis includes a breakdown of indicators like MACD, RSI, and moving averages, offering buy, sell, and neutral signals for investors.
CERT|Certara Inc|Price:7.915|Chg%:+0.165
This article provides a comprehensive stock analysis of Certara Inc (CERT) by TradingKey, focusing on its fundamentals, valuation, growth potential, and institutional ownership. It highlights Certara's healthy fundamentals and high growth potential, classifying its valuation as fairly valued within the Software & IT Services industry. The analysis also covers analyst ratings, stock performance trends, and key strengths and risks associated with the company.
